Semaglutide vs. Tirzepatide: What’s the Difference?

If you've been researching medical weight management, you've probably come across two names again and again:

Semaglutide.

Tirzepatide.

Both have become widely discussed options for people seeking medical support with weight management. Both are injectable medications used once weekly for their FDA-approved weight-management indications, and both work in ways that can influence appetite, food intake, and metabolic processes.

But they are not the same medication.

Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors.

So which one is better?

The answer isn't simply “the strongest one.”

The right medication depends on your health history, goals, response to treatment, tolerability, other medications, and the clinical judgment of your healthcare provider.

Let's break down the differences.

First: What Are Semaglutide and Tirzepatide?

Semaglutide and tirzepatide belong to a newer generation of medications that have changed the conversation around medical weight management.

Semaglutide

Semaglutide is a GLP-1 receptor agonist.

For weight management, the FDA-approved brand Wegovy® is indicated, along with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight plus at least one weight-related condition. Its current U.S. labeling also includes certain cardiovascular and liver-related indications.

Semaglutide is also used under other brand names for different medical indications, including type 2 diabetes.

Tirzepatide

Tirzepatide works differently.

It activates both:

• GIP receptors

• GLP-1 receptors

The FDA-approved weight-management brand Zepbound® is indicated, alongside a reduced-calorie diet and increased physical activity, for chronic weight management in adults with obesity or adults with overweight plus at least one weight-related condition. Its current U.S. labeling also includes an indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

This dual mechanism is one of the major differences between the two medications.

Semaglutide vs. Tirzepatide at a Glance

FDA-approved indications can change; patients should review current prescribing information with their healthcare professional.

How Does Semaglutide Work?

Semaglutide mimics the activity of GLP-1, a hormone involved in regulating blood glucose and appetite.

GLP-1 receptor activation can influence appetite and food intake and can slow gastric emptying.

The result for some patients is that they may:

• Feel full sooner

• Experience reduced appetite

• Eat less

• Have fewer hunger cues

• Find it easier to maintain a reduced-calorie eating pattern

That doesn't mean semaglutide works the same way for everyone.

Individual responses vary, and treatment generally involves gradual dose escalation to improve tolerability.

How Does Tirzepatide Work?

Tirzepatide takes a slightly different approach.

It activates both GIP and GLP-1 receptors.

Because it targets two hormone pathways rather than one, tirzepatide is sometimes described as a dual GIP/GLP-1 receptor agonist.

Like semaglutide, it can influence appetite, food intake, gastric emptying, and glucose regulation.

The difference in mechanism is one reason researchers have been interested in comparing the two medications directly.

Which One Produces More Weight Loss?

This is one of the biggest questions people ask.

And now we have direct head-to-head clinical evidence.

The SURMOUNT-5 trial, published in The New England Journal of Medicine in 2025, compared tirzepatide and semaglutide in 751 adults with obesity who did not have type 2 diabetes.

After 72 weeks:

• Participants receiving tirzepatide had an average weight change of approximately −20.2%

• Participants receiving semaglutide had an average weight change of approximately −13.7%

Tirzepatide also produced a greater average reduction in waist circumference in that trial.

So, in this particular head-to-head study, tirzepatide produced greater average weight reduction than semaglutide.

But that doesn't mean tirzepatide is automatically the right choice for every person.

Clinical decisions involve much more than one number.

Does “More Weight Loss” Automatically Mean “Better”?

Not necessarily.

A medication should be evaluated based on the whole patient, not just the percentage on the scale.

Your provider may consider:

• Your current weight and BMI

• Weight-related health conditions

• Blood glucose

• Blood pressure

• Cardiovascular risk

• Sleep apnea

• Gastrointestinal history

• Other medications

• Previous weight-management attempts

• Treatment goals

• Side-effect tolerance

• Cost and access

• Pregnancy plans

• Your ability to maintain treatment over time

A medication that produces excellent results but causes unacceptable side effects may not be the best fit.

Likewise, a medication that produces somewhat less weight loss but is well tolerated and sustainable may be a better choice for a particular patient.

What Side Effects Can Occur?

Both medications can cause gastrointestinal side effects.

Common adverse reactions listed in the prescribing information include symptoms such as:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Abdominal discomfort or pain

• Indigestion

For tirzepatide, the current prescribing information also lists injection-site reactions, fatigue, belching, hair loss, and gastroesophageal reflux disease among adverse reactions reported in clinical studies.

For semaglutide, gastrointestinal effects are also among the most common adverse reactions.

These symptoms are often most noticeable during dose escalation, although individual experiences vary. In the SURMOUNT-5 trial, gastrointestinal adverse events were the most common in both treatment groups and were primarily mild to moderate, particularly during dose escalation.

Why Is Dose Escalation Gradual?

Your body needs time to adjust.

Both medications are generally started at a lower dose and increased gradually according to the prescribing information and individual tolerability.

The purpose isn't simply to reach the highest dose as quickly as possible.

It's to find an effective dose that the patient can tolerate.

The current Zepbound prescribing information, for example, recommends starting at 2.5 mg once weekly for four weeks and increasing in 2.5-mg increments after at least four weeks, with maintenance dosing selected based on response and tolerability.

More medication isn't automatically better.

Your healthcare provider should determine the appropriate dose and schedule.

What About the “GLP-1” Terminology?

You'll often hear semaglutide and tirzepatide both called GLP-1 medications.

That's understandable, but there's a distinction.

Semaglutide

Primarily targets the GLP-1 receptor.

Tirzepatide

Targets both GIP and GLP-1 receptors.

This dual activity is why tirzepatide is technically a GIP/GLP-1 receptor agonist, rather than simply a GLP-1 receptor agonist.

Can These Medications Replace Diet and Exercise?

No.

Both Wegovy and Zepbound are FDA-approved for use in combination with a reduced-calorie diet and increased physical activity for their weight-management indications.

That is an important part of the treatment philosophy.

Medication can support appetite regulation and weight management.

But long-term health also depends on:

• Nutrition

• Protein intake

• Fiber

• Physical activity

• Strength training

• Sleep

• Stress management

• Hydration

• Behavioral changes

The goal shouldn't simply be:

“How much weight can I lose?”

A better question is:

“How can I improve my health and build habits I can maintain?”

Semaglutide vs. Tirzepatide: Which One Is Better for Appetite?

Both can reduce appetite.

But individual responses can differ.

Some patients may experience substantial appetite reduction with semaglutide.

Others may respond more strongly to tirzepatide.

And some may find one medication easier to tolerate than the other.

There is no reliable way to determine your individual response simply by looking at someone else's results online.

Your experience is your own.

What About Metabolic Health?

Weight management is only one part of the picture.

Both medications affect pathways involved in glucose regulation.

Semaglutide is an established GLP-1 receptor agonist used for type 2 diabetes under brands including Ozempic®. Its FDA-approved labeling includes improving glycemic control and certain cardiovascular and kidney-risk indications in adults with type 2 diabetes.

Tirzepatide's dual GIP/GLP-1 activity also affects glucose regulation, and tirzepatide is marketed as Mounjaro® for type 2 diabetes.

This is one reason these medications have become important in the broader conversation around metabolic health.

However, a weight-management program should not assume that everyone needs the same medication or that weight is the only health metric that matters.

An Important Note About Compounded Semaglutide and Tirzepatide

This is especially important if you're researching online weight-management programs.

You may encounter compounded semaglutide or compounded tirzepatide offered by clinics or pharmacies.

Compounded drugs are not FDA-approved, meaning the FDA does not review them before marketing for safety, effectiveness, or quality in the same way it reviews approved drugs. The FDA says compounded medications can serve an important medical need when an FDA-approved medication cannot meet that need, but they also carry additional risks.

The FDA has specifically reported concerns involving compounded semaglutide and tirzepatide, including dosing errors, fraudulent products, and adverse-event reports. As of May 31, 2026, the agency reported 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, while noting that these reports do not establish causation in every case.

What should patients do?

Ask:

• Who prescribed the medication?

• What pharmacy compounded it?

• Is the pharmacy properly licensed?

• What exactly is the concentration?

• How is the dose measured?

• What are the instructions?

• Who do I contact if I experience side effects?

• Why is a compounded product medically appropriate for me?

The FDA recommends that compounded GLP-1 medications be used only when a patient's medical needs cannot be met by an FDA-approved drug and advises obtaining a prescription from a doctor and using a state-licensed pharmacy.

Can You Take Semaglutide and Tirzepatide Together?

They should not be combined unless specifically directed in an appropriate clinical setting.

The current Zepbound prescribing information states that coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended.

That means patients should never attempt to combine these medications on their own.

If you're considering switching from one medication to another, your provider should determine the appropriate transition.

Who May Be a Candidate for Medical Weight Management?

Medical weight management isn't simply about wanting to lose a few pounds.

FDA-approved indications for Wegovy and Zepbound generally focus on adults with obesity, or adults with overweight plus at least one weight-related condition, in combination with diet and physical activity.

Your provider may also consider:

• Medical history

• Current medications

• Weight trajectory

• BMI

• Existing health conditions

• Previous weight-management strategies

• Lifestyle factors

• Treatment goals

A consultation is important because a medication that is appropriate for one person may not be appropriate for another.

Who Should Not Take These Medications?

There are important contraindications and precautions.

Both semaglutide and tirzepatide products carry a boxed warning concerning thyroid C-cell tumors based on findings in rodents. The medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other medical considerations may include:

• History of certain gastrointestinal problems

• Pancreatitis

• Gallbladder disease

• Kidney problems

• Severe gastrointestinal reactions

• Diabetic retinopathy in certain patients

• Pregnancy

• Certain medications

For example, the current Zepbound label states that it may cause fetal harm and should be discontinued when pregnancy is recognized.

This is why these medications should be prescribed and monitored by qualified healthcare professionals.

Semaglutide vs. Tirzepatide: Which One Is Right for You?

There is no universal winner.

The clinical evidence suggests that tirzepatide produced greater average weight reduction than semaglutide in the SURMOUNT-5 head-to-head trial, but the choice of medication still needs to be individualized.

Your provider may ultimately recommend:

Semaglutide

If its mechanism, indication, medical profile, availability, tolerability, or other factors make it appropriate for you.

Tirzepatide

If its dual GIP/GLP-1 mechanism, clinical profile, or your treatment goals make it a suitable option.

Neither

Sometimes the best answer is not starting a medication at all.

Lifestyle changes, evaluation of underlying medical conditions, nutritional support, physical activity, sleep, behavioral strategies, or another approach may be more appropriate.

The goal isn't to choose the most popular medication.

It's to choose the most appropriate plan.

Medical Weight Management Is More Than the Medication

A successful weight-management program should look beyond the prescription.

Think about the complete picture.

Nutrition

Are you eating enough protein and fiber while maintaining a sustainable calorie intake?

Movement

Are you incorporating cardiovascular activity and resistance training?

Sleep

Are you getting adequate rest?

Hydration

Are you maintaining regular hydration?

Muscle Preservation

Are you supporting lean mass while losing weight?

Behavior

Are you building habits that can continue beyond the initial phase of treatment?

Medical Monitoring

Are you being appropriately monitored for response, tolerability, and potential side effects?

That's what makes medical weight management personalized.

What Happens When You Stop?

This is a question that deserves more attention.

Weight management medications are not necessarily short-term “quick fixes.”

Weight regain can occur after stopping treatment, particularly if appetite returns and the underlying factors contributing to weight gain remain.

That doesn't mean treatment has failed.

It means obesity and excess weight can be chronic, complex conditions influenced by biology, environment, behavior, medications, sleep, stress, and other factors.

Your provider can help determine whether treatment should continue, change, or transition based on your individual goals and health.

A Personalized Approach at Coastal Wellness Collective

At Coastal Wellness Collective, medical weight management can be approached as more than simply choosing between two medications.

The first step is understanding you.

A personalized consultation may consider:

• Your health history

• Your current weight and goals

• Your lifestyle

• Your nutrition

• Your activity level

• Your medications

• Potential contraindications

• Your treatment preferences

• Your response to previous weight-management strategies

From there, a qualified provider can determine whether a medication such as semaglutide or tirzepatide may be appropriate.

The goal is not simply a smaller number on the scale.

It's a healthier, more sustainable approach to weight management.

Semaglutide vs. Tirzepatide: Quick Takeaway

If you remember only five things, remember these:

1. They work differently.

Semaglutide activates GLP-1 receptors, while tirzepatide activates both GIP and GLP-1 receptors.

2. Both can support weight management.

Both are FDA-approved for appropriate patients as part of a comprehensive approach involving reduced-calorie eating and increased physical activity.

3. Tirzepatide produced greater average weight loss in a direct comparison.

In SURMOUNT-5, average weight reduction at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide.

4. Side effects and medical history matter.

Gastrointestinal symptoms are common with both, particularly during dose escalation.

5. There is no “best” medication for everyone.

The right choice depends on your individual health profile, goals, response, tolerability, and provider's clinical judgment.

Frequently Asked Questions

Is tirzepatide stronger than semaglutide?

In the 72-week SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without type 2 diabetes. However, individual responses vary, and “stronger” does not automatically mean “better” for every patient.

Is semaglutide a GLP-1?

Yes. Semaglutide is a GLP-1 receptor agonist.

Is tirzepatide a GLP-1?

Tirzepatide activates both GIP and GLP-1 receptors, so it is more accurately described as a dual GIP/GLP-1 receptor agonist.

Which has fewer side effects, semaglutide or tirzepatide?

Both can cause gastrointestinal side effects, and there isn't a single medication that is guaranteed to be easier for everyone. Individual tolerability varies. In SURMOUNT-5, gastrointestinal events were the most common adverse events with both treatments.

Can I switch from semaglutide to tirzepatide?

A healthcare professional may determine that switching is appropriate for some patients, but the transition should be medically supervised. Do not switch, combine, or change doses on your own.

Can I take semaglutide and tirzepatide together?

They should not be combined unless specifically directed by a qualified healthcare professional. The current Zepbound prescribing information does not recommend coadministration with other GLP-1 receptor agonists or tirzepatide-containing products.

Are compounded semaglutide and tirzepatide FDA-approved?

No. Compounded drugs are not FDA-approved, and the FDA does not review them before marketing for safety, effectiveness, or quality in the same manner as approved drugs.

Does medication replace diet and exercise?

No. FDA-approved Wegovy and Zepbound weight-management indications are used alongside reduced-calorie eating and increased physical activity.

Ready to Find the Right Weight-Management Approach for You?

Semaglutide and tirzepatide have changed the possibilities for medical weight management—but choosing between them shouldn't be based on social media trends, someone else's results, or which medication sounds “stronger.”

Your health history matters.
Your goals matter.
Your response matters.
Your long-term plan matters.

At Coastal Wellness Collective, a personalized consultation can help you explore whether medical weight management may be appropriate and discuss options such as semaglutide or tirzepatide under qualified medical supervision.

Visit CoastalWellnessStPete.com or call 727-209-7110 to schedule a consultation.

Medical & Wellness Disclaimer

This article is for general educational and informational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment. Semaglutide and tirzepatide are prescription medications and may not be appropriate for everyone. FDA-approved indications, labeling, contraindications, warnings, and dosing recommendations can change and should be reviewed with a qualified healthcare professional. Compounded medications are not FDA-approved and may carry additional quality and dosing considerations. Never start, stop, combine, or change the dose of a prescription medication without guidance from your prescribing clinician. Individual results and side effects vary.